Research Papers

This database includes peer-reviewed publications authored by TB Alliance staff. Use the tags on the left to filter by subject, or search for a particular author or term using the search bar.

Tag: Pretomanid/PA-824

Displaying 53 papers

Treatment of Highly Drug-Resistant Pulmonary Tuberculosis

Publication: The New England Journal of Medicine

Author(s): Francesca Conradie, M.B., B.Ch., Andreas H. Diacon, M.D., Nosipho Ngubane, M.B., B.Ch., Pauline Howell, M.B., B.Ch., Daniel Everitt, M.D., Angela M. Crook, Ph.D., Carl M. Mendel, M.D., Erica Egizi, M.P.H., et al., for the Nix-TB Trial Team*

3/2020

Tags: Bedaquiline (TMC-207), BPaL, Clinical Trial Results, Linezolid, MDR-TB, Pretomanid/PA-824, Regimen Change, Trial Design, XDR-TB

Bedaquiline, moxifloxacin, pretomanid, and pyrazinamide during the first 8 weeks of treatment of patients with drug-susceptible or drug-resistant pulmonary tuberculosis: a multicentre, open-label, partially randomised, phase 2b trial

Publication: The Lancet Respiratory Medicine

Author(s): Conor D Tweed, Rodney Dawson, Divan A Burger, Almari Conradie, Angela M Crook, Carl M Mendel, Francesca Conradie, Andreas H Diacon, Nyanda E Ntinginya, Daniel E Everitt, Frederick Haraka, Mengchun Li, Christo H van Niekerk, Alphonse Okwera

11/2019

Tags: Bedaquiline (TMC-207), BPaZ, Clinical Trial Results, MDR-TB, Moxifloxacin, NC-005, PaMZ, Pretomanid/PA-824, Trial Design

Population Pharmacokinetics of the Antituberculosis Agent Pretomanid

Publication: Antimicrobial Agents and Chemotheraphy

Author(s): David H. Salinger, Vishak Subramoney, Daniel Everitt, Jerry R. Nedelman

8/2019

Tags: BPaL, Pharmacokinetics, Pretomanid/PA-824

Long-Term Effects on QT Prolongation of Pretomanid Alone and in Combinations in Patients with Tuberculosis

Publication: Antimicrobial Agents and Chemotheraphy

Author(s): Hanbin Li, David H. Salinger, Daniel Everitt, Mengchun Li, Angelo Del Parigi, Carl Mendel, Jerry R. Nedelman

7/2019

Tags: BPaL, Pharmacodynamics, Pretomanid/PA-824

Contribution of Pretomanid to Novel Regimens Containing Bedaquiline with either Linezolid or Moxifloxacin and Pyrazinamide in Murine Models of Tuberculosis

Publication: Antimicrobial Agents and Chemotheraphy

Author(s): Xu J, Li SY, Almeida DV, Tasneen R, Barnes-Boyle K, Converse PJ, Upton, Mdluli, Fotouhi, Nuermberger EL

4/2019

Tags: Bedaquiline (TMC-207), BPaL, Linezolid, Moxifloxacin, Pretomanid/PA-824, Pyrazinamide

Antitubercular nitroimidazoles revisited: synthesis and activity of the authentic 3-nitro isomer of pretomanid

Publication: ACS Medicinal Chemistry Letters

Author(s): Andrew M. Thompson, Muriel Bonnet, Ho H. Lee, Scott G. Franzblau, Baojie Wan, George S. Wong, Christopher B. Cooper, William A. Denny

12/2017

Tags: Pretomanid/PA-824

Bactericidal Activity of Pyrazinamide and Clofazimine Alone and in Combinations with Pretomanid and Bedaquiline

Publication: Diacon AH, Dawson R, von Groote-Bidlingmaier F, et. al. Bactericidal activity of pyrazinamide and clofazimine alone and in combinations with pretomanid and bedaquiline. Am J Respir Crit Care Med. 2015 Apr 15;191(8):943-53. doi: 10.1164/rccm.201410-1801OC.

4/2015

Tags: Bedaquiline (TMC-207), BPaZ, Clinical Development, Clinical Trial Results, Clofazamine, NC-003, Pretomanid/PA-824, Pyrazinamide, TB-HIV

Contribution of the Nitroimidazoles PA-824 and TBA-354 to the Activity of Novel Regimens in Murine Models of Tuberculosis

Publication: Tasneen R, Williams K, Amoabeng O, Minkowski A, Mdluli KE, Upton AM, Nuermberger EL. Contribution of the nitroimidazoles PA-824 and TBA-354 to the activity of novel regimens in murine models of tuberculosis. Antimicrob Agents Chemother. 2015 Jan;59(1):129

1/2015

Tags: Drug Discovery, Linezolid, Preclinical Data, Pretomanid/PA-824, Pyrazinamide, Sutezolid, TBA-354

Phase I safety, pharmacokinetics, and pharmacogenetics study of the antituberculosis drug PA-824 withconcomitant lopinavir-ritonavir, efavirenz, or rifampin

Publication: Dooley KE, Luetkemeyer AF, Park JG, et. al. Phase I safety, pharmacokinetics, and pharmacogenetics study of the antituberculosis drug PA-824 with concomitant lopinavir-ritonavir, efavirenz, or rifampin. Antimicrob Agents Chemother. 2014 Sep;58(9):5245-52.

9/2014

Tags: Clinical Development, Clinical Trial Results, Pharmacokinetics, Pretomanid/PA-824, TB-HIV

1,4-Azaindole, a Potential Drug Candidate for Treatment of Tuberculosis

Publication: Chatterji M, Shandil R, Manjunatha MR, et. al. 1,4-azaindole, a potential drug candidate for treatment of tuberculosis.Antimicrob Agents Chemother. 2014 Sep;58(9):5325-31. doi: 10.1128/AAC.03233-14.

6/2014

Tags: Bedaquiline (TMC-207), Drug Discovery, MDR-TB, Pharmacokinetics, Preclinical Data, Pretomanid/PA-824

Effect of a high-calorie, high-fat meal on the bioavailability and pharmacokinetics of PA-824 in healthy adult subjects

Publication: Winter H, Ginsberg A, Egizi E, et. al. Effect of a High-Calorie, High-Fat Meal on the Bioavailability and Pharmacokinetics of PA-824 in Healthy Adult Subjects. Antimicrob Agents Chemother. 2013 Nov; 57(11): 5516–5520. doi: 10.1128/AAC.00798-13

11/2013

Tags: Clinical Development, Clinical Trial Results, Pharmacodynamics, Pretomanid/PA-824

Potent rifamycin-sparing regimen cures guinea pig tuberculosis as rapidly as the standard regimen

Publication: Dutta NK, Alsultan A, Gniadek TJ, et. al. Potent rifamycin-sparing regimen cures guinea pig tuberculosis as rapidly as the standard regimen. Antimicrob Agents Chemother. 2013 Aug;57(8):3910-6. doi: 10.1128/AAC.00761-13.

8/2013

Tags: HRZE, Moxifloxacin, PaMZ, Preclinical Data, Pretomanid/PA-824, Pyrazinamide

Evaluation of pharmacokinetic interaction between PA-824 and midazolam in healthy adult subjects

Publication: Winter H, Egizi E, Erondu N, et. al. Evaluation of Pharmacokinetic Interaction between PA-824 and Midazolam in Healthy Adult Subjects. Antimicrob Agents Chemother. 2013 Aug; 57(8): 3699–3703.doi: 10.1128/AAC.02632-12

4/2013

Tags: Clinical Development, Clinical Trial Results, Pretomanid/PA-824

Early bactericidal activity of new drug regimens for tuberculosis - Authors' reply

Publication: Diacon AH, Donald PR, Mendel CM. Early bactericidal activity of new drug regimens for tuberculosis - Authors' reply. Lancet. 2013 Jan 12;381(9861):112-3. doi: 10.1016/S0140-6736(13)60042-2.

1/2013

Tags: Clinical Development, Editorials, Moxifloxacin, NC-001, PaMZ, Pretomanid/PA-824, Pyrazinamide, Trial Design

Sterilizing Activities of Novel Combinations Lacking First- and Second-Line Drugs in a Murine Model of Tuberculosis

Publication: Williams K, Minkowski A, Amoabeng O, et. al. Sterilizing activities of novel combinations lacking first- and second-line drugs in a murine model of tuberculosis. Antimicrob Agents Chemother. 2012 Jun;56(6):3114-20. doi: 10.1128/AAC.00384-12.

4/2012

Tags: Bedaquiline (TMC-207), Clofazamine, Preclinical Data, Pretomanid/PA-824, Pyrazinamide, Rifapentine, Sutezolid

New Drugs for the Treatment of Tuberculosis: Needs, Challenges, Promise, and Prospects for the Future

Publication: Lienhardt C, Raviglione M, Spigelman M, et. al. New drugs for the treatment of tuberculosis: needs, challenges, promise, and prospects for the future. J Infect Dis. 2012 May 15;205 Suppl 2:S241-9. doi: 10.1093/infdis/jis034.

3/2012

Tags: Advocacy, Childhood TB, Clinical Development, Drug Discovery, Drug-Sensitivity Testing, Editorials, Global Pipeline, MDR-TB, Moxifloxacin, Pharmacodynamics, Pharmacokinetics, Policy, Preclinical Models, Pretomanid/PA-824, Regimen Change, TB Market, TB-HIV, Trial Design

Phase II dose-ranging trial of the early bactericidal activity of PA-824

Publication: Diacon AH, Dawson R, du Bois J, et. al. Phase II dose-ranging trial of the early bactericidal activity of PA-824. Antimicrob Agents Chemother. 2012 Jun;56(6):3027-31. doi: 10.1128/AAC.06125-11

3/2012

Tags: Clinical Development, Clinical Trial Results, Pharmacokinetics, Pretomanid/PA-824

14-day bactericidal activity of PA-824, bedaquiline, pyrazinamide, and moxifloxacin combinations: a randomised trial.

Publication: Diacon AH, Dawson R, von Groote-Bidlingmaier F, et. al. 14-day bactericidal activity of PA-824, bedaquiline, pyrazinamide, and moxifloxacin combinations: a randomised trial. Lancet. 2012 Sep 15;380(9846):986-93. doi: 10.1016/S0140-6736(12)61080-0.

9/2011

Tags: Bedaquiline (TMC-207), Clinical Development, Clinical Trial Results, MDR-TB, Moxifloxacin, NC-001, PaMZ, Pretomanid/PA-824, Pyrazinamide

Sterilizing activity of novel TMC207- and PA-824-containing regimens in a murine model of tuberculosis

Publication: Tasneen R, Li SY, Peloquin CA, et. al. Sterilizing activity of novel TMC207- and PA-824-containing regimens in a murine model of tuberculosis. Antimicrob Agents Chemother. 2011 Dec;55(12):5485-92. doi: 10.1128/AAC.05293-11

9/2011

Tags: Bedaquiline (TMC-207), BPaZ, Clofazamine, Preclinical Data, Pretomanid/PA-824

Pages